Patrik Sebastian Jeanmonod
Net Worth

Last updated:

What is Patrik Sebastian Jeanmonod net worth?

The estimated net worth of Mr. Patrik Sebastian Jeanmonod is at least $1,978,826 as of 11 Mar 2024. He owns shares worth $377,336 as insider, has earned $581,160 from insider trading and has received compensation worth at least $1,020,330 in Cytek Biosciences, Inc..

What is the salary of Patrik Sebastian Jeanmonod?

Mr. Patrik Sebastian Jeanmonod salary is $340,110 per year as Chief Financial Officer in Cytek Biosciences, Inc..

How old is Patrik Sebastian Jeanmonod?

Mr. Patrik Sebastian Jeanmonod is 59 years old, born in 1966.

What stocks does Patrik Sebastian Jeanmonod currently own?

As insider, Mr. Patrik Sebastian Jeanmonod owns shares in one company:

Company Title Shares Price per share Total value
Cytek Biosciences, Inc. (CTKB) Chief Financial Officer 93,400 $4.04 $377,336

What does Cytek Biosciences, Inc. do?

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Patrik Sebastian Jeanmonod insider trading

Cytek Biosciences, Inc.

Mr. Patrik Sebastian Jeanmonod has made 18 insider trades between 2022-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 4,908 units of CTKB stock on 11 Mar 2024. As of 11 Mar 2024 he still owns at least 93,400 units of CTKB stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 4,908 N/A N/A
Option
Restricted Stock Units 4,908 N/A N/A
Option
Restricted Stock Units 1,752 N/A N/A
Option
Common Stock 1,752 N/A N/A
Sale
Common Stock 3,000 $9.5 $28,500
Sale
Common Stock 3,000 $6.94 $20,820
Option
Common Stock 1,752 N/A N/A
Option
Common Stock 3,681 N/A N/A
Option
Restricted Stock Units 1,752 N/A N/A
Option
Restricted Stock Units 3,681 N/A N/A
Sale
Common Stock 3,000 $4.68 $14,040
Sale
Common Stock 3,000 $6.38 $19,140
Sale
Common Stock 3,000 $7.69 $23,070
Option
Restricted Stock Units 3,681 N/A N/A
Option
Common Stock 1,752 N/A N/A
Option
Restricted Stock Units 1,752 N/A N/A
Option
Common Stock 3,681 N/A N/A
Sale
Common Stock 3,000 $9.17 $27,510
Sale
Common Stock 3,000 $7.96 $23,880
Sale
Common Stock 3,000 $7.76 $23,280
Option
Restricted Stock Units 2,454 N/A N/A
Option
Restricted Stock Units 1,752 N/A N/A
Option
Common Stock 1,752 N/A N/A
Option
Common Stock 2,454 N/A N/A
Sale
Common Stock 3,000 $10.24 $30,720
Sale
Common Stock 3,000 $8.33 $24,990
Sale
Common Stock 3,000 $11.05 $33,150
Option
Restricted Stock Units 1,752 N/A N/A
Option
Common Stock 1,752 N/A N/A
Sale
Common Stock 3,500 $11.05 $38,675
Sale
Common Stock 3,500 $9.77 $34,195
Sale
Common Stock 3,500 $14.3 $50,050
Option
Common Stock 1,752 N/A N/A
Option
Restricted Stock Units 1,752 N/A N/A
Sale
Common Stock 3,500 $15.16 $53,060
Sale
Common Stock 3,500 $12.63 $44,205
Sale
Common Stock 3,500 $13.45 $47,075
Option
Common Stock 1,752 N/A N/A
Option
Restricted Stock Units 1,752 N/A N/A
Sale
Common Stock 3,500 $12.8 $44,800
Option
Restricted Stock Units 2,336 N/A N/A
Option
Common Stock 2,336 N/A N/A

Cytek Biosciences key executives

Cytek Biosciences, Inc. executives and other stock owners filed with the SEC: